Johnson & Johnson: Cuts FY26 Adjusted EPS Outlook To $10.96-$11.11 (est $11.69)

Expects 2026 Adjusted Operational EPS And Adjusted EPS To Decline By $0.64 - Expects 2027 Adjusted Operational EPS And Adjusted EPS To Decline By $1.36 - Enters Strategic Agreements With Sail Biomedicines - Granted Exclusive Option To Acquire Sail Biomedicines For $2.58B - Will Also Make An Equity Investment In Sail Biomedicines